Literature DB >> 19761435

Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.

Ana Paula de Souza1, Cristina Bonorino.   

Abstract

The interactions between cancer cells and host immune cells in tumoral microenvironments create an immunosuppressive network that promotes tumor growth, protects the tumor from immune attack and attenuates the efficacy of immunotherapeutic approaches. The development of immune tolerance becomes predominant in the immune system of patients with advanced-stage tumors. Several mechanisms have been described by which tumors can suppress the immune system, including secretion of cytokines, alterations in antigen-presenting cell subsets, costimulatory and coinhibitory molecule alterations and altered ratios of Tregs to effector T cells. It is well demonstrated that these mechanisms of immunosuppression can impair tumor specific immune responses. However, it is not well established whether this immunosuppressive environment can affect immune responses to nontumor antigens, specifically in regard to priming and the development of memory. The few existing studies indicate that responses to nontumor antigens seem unaffected, although there is still a deep lack of understanding of this phenomenon. This is an important issue regarding patient endurance and quality of life. Here, we review the existing evidence on immunosuppression promoted by tumors, with particular attention to its impact on specific immune responses. Understanding these interactions can help us subvert tumor-induced tolerance and optimize anti-tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19761435     DOI: 10.1586/era.09.88

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN: 1473-7140            Impact factor:   4.512


  29 in total

Review 1.  Vitamin D and cancer: a review of molecular mechanisms.

Authors:  James C Fleet; Marsha DeSmet; Robert Johnson; Yan Li
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

Review 2.  Modulation of T cell immune functions by the prostaglandin E(2) - cAMP pathway in chronic inflammatory states.

Authors:  Kristoffer Watten Brudvik; Kjetil Taskén
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 3.  Combination of celecoxib (Celebrex®) and CD19 CAR-redirected CTL immunotherapy for the treatment of B-cell non-Hodgkin's lymphomas.

Authors:  Tam Nm Dinh; Alexandra S Onea; Ali R Jazirehi
Journal:  Am J Clin Exp Immunol       Date:  2017-05-15

4.  Host b7x promotes pulmonary metastasis of breast cancer.

Authors:  Yael M Abadi; Hyungjun Jeon; Kim C Ohaegbulam; Lisa Scandiuzzi; Kaya Ghosh; Kimberly A Hofmeyer; Jun Sik Lee; Anjana Ray; Claudia Gravekamp; Xingxing Zang
Journal:  J Immunol       Date:  2013-03-01       Impact factor: 5.422

5.  A potential therapy for chordoma via antibody-dependent cell-mediated cytotoxicity employing NK or high-affinity NK cells in combination with cetuximab.

Authors:  Rika Fujii; Jeffrey Schlom; James W Hodge
Journal:  J Neurosurg       Date:  2017-07-28       Impact factor: 5.115

6.  Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects.

Authors:  Alexander L Rakhmilevich; Mark J Baldeshwiler; Tyler J Van De Voort; Mildred A R Felder; Richard K Yang; Nicholas A Kalogriopoulos; David S Koslov; Nico Van Rooijen; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2012-03-06       Impact factor: 6.968

7.  An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.

Authors:  Jian-Wen Cheng; Ying-Hong Shi; Jia Fan; Xiao-Wu Huang; Shuang-Jian Qiu; Yong-Sheng Xiao; Zheng Wang; Zhi Dai; Zhao-You Tang; Jian Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

8.  Splenectomy inhibits non-small cell lung cancer growth by modulating anti-tumor adaptive and innate immune response.

Authors:  Liran Levy; Inbal Mishalian; Rachel Bayuch; Lida Zolotarov; Janna Michaeli; Zvi G Fridlender
Journal:  Oncoimmunology       Date:  2015-01-22       Impact factor: 8.110

9.  The androgen receptor: a biologically relevant vaccine target for the treatment of prostate cancer.

Authors:  Brian M Olson; Laura E Johnson; Douglas G McNeel
Journal:  Cancer Immunol Immunother       Date:  2012-10-30       Impact factor: 6.968

10.  Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer.

Authors:  Anqing Zhu; Huizi Sha; Shu Su; Fangjun Chen; Jia Wei; Fanyan Meng; Yang Yang; Juan Du; Jie Shao; Fuzhi Ji; Chong Zhou; Zhengyun Zou; Xiaoping Qian; Baorui Liu
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.